Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury

Neurogenic Detrusor Overactivity Clinical Trial

Official title:

A Prospective, Multi-center, Open-label Study of Trospium Delivered Intravesically by TAR-302-5018 to Spinal Cord Injury Subjects With Neurogenic Detrusor Overactivity (NDO)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03168828
• Other study ID #: TAR-302-101
• Status: Completed
• Phase: Phase 1
• Start date: April 24, 2017
• Est. completion date: July 26, 2018

Study information

• Verified date: January 2020
• Source: Taris Biomedical LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if TAR-302-5018, an investigational drug-delivery system, is safe and tolerable in patients with neurogenic detrusor overactivity (NDO) resulting from spinal cord injury (SCI).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: July 26, 2018
• Est. primary completion date: July 26, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

1. Diagnosis of traumatic or nontraumatic suprasacral SCI for longer than 6 months and a documented history of NDO.

2. Age = 18 years.

3. Demonstrated competence in and currently uses intermittent catheterization (IC) to empty the bladder (minimum of 4 IC events/day).

• No indwelling catheter permitted

• Caregiver may perform IC

• Subject must be willing to maintain an established IC frequency throughout the study

4. History of non-stress-based urinary incontinence.

Exclusion Criteria

1. Participation in another drug or device study within 60 days prior to the screening visit.

2. Previous urologic surgery that either decreases outlet resistance (transurethral prostatectomy, urethral stent, sphincterotomy) or changes native bladder anatomy (bladder augmentation).

3. Presence of significant renal dysfunction at screening (Glomerular Filtration Rate < 30 mL/min).

4. Presence of significant polyuria of any cause at screening (urine output > 4,000 mL/day).

5. History of pelvic radiation.

6. History of either bladder cancer or bladder pathology that the investigator deems unfit for study inclusion.

7. Active malignancies within 12 months with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome.

8. Symptomatic autonomic dysreflexia requiring ongoing treatment.

9. In the opinion of the investigator, the subject has a history of significant stress urinary incontinence.

10. Subjects with active bladder stones or history of bladder stones < 6 months prior to study entry.

11. History of recurrent symptomatic UTIs (> 6 per 1 year).

12. Subjects with either untreated urinary retention or gastric retention or uncontrolled narrow-angle glaucoma.

13. Subjects with known hypersensitivity to trospium or chemically-related drugs.

14. Subjects with known hypersensitivity to nitinol or silicone.

15. Subjects actively taking oral trospium. If previously used and discontinued, these medications must have been stopped for >2 weeks.

16. The addition of a new or a change in dose to a current medication for the treatment of OAB (i.e. anticholinergics, beta-3 adrenergic agonists, antispasmodics, antidepressants, or hormones) within 30 days prior to signing the Informed Consent Form (ICF). A current dose must continue through the final study visit. If previously used and discontinued, these medications must have been stopped for > 2 weeks prior to Day 0.

17. Intravesical onabotulinum toxin use within the last 9 months prior to the screening visit.

18. Intravesical anticholinergic medications within the last 30 days prior to the screening visit.

19. History of non-medication based therapy (i.e. Interstim therapy) for the treatment of OAB. History of non-invasive neuromodulation (i.e. Percutaneous Tibial Nerve Stimulation (PTNS)) is allowed if discontinued at least 8 weeks prior to Study Day 0.

20. Female subject who is pregnant (as verified by urine test at time of screening) or lactating or of childbearing potential and not using acceptable methods of contraception.

21. Subject has a medical condition that may cause noncompliance with the study protocol.

22. Subject refuses to provide written informed consent.

23. Subject will be unable or unwilling to complete the questionnaires, diaries, or attend all protocol mandated study visits.

24. Presence of any bladder or urethral anatomic feature that in the opinion of the investigator may prevent the safe placement, indwelling use or removal of TAR-302-5018.

25. History or presence of any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, gynecological, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder that, in the opinion of the investigator, contraindicates participation.

26. History of any of the following within 3 months prior to Screening Visit:

1. Major illness/major surgery (requiring hospitalization), including pelvic, lower back surgery or procedure unrelated to bladder cancer; most outpatient procedures are not exclusionary

2. Renal or ureteral stone disease or instrumentation

3. Childbirth

27. Difficulty providing blood samples.

28. Other unspecified reasons that, in the opinion of the investigator or TARIS, make the subject unsuitable for enrollment.

Related Conditions & MeSH terms

• Neurogenic Detrusor Overactivity
• Spinal Cord Injuries

Intervention

Drug:
• Trospium-Releasing Intravesical System (TAR-302-5018)
TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.

Locations

Country	Name	City	State
United States	Carolinas HealthCare System	Charlotte	North Carolina
United States	Virginia Mason	Seattle	Washington
United States	Michigan Institute of Urology	Troy	Michigan
United States	Urology of Virginia	Virginia Beach	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Taris Biomedical LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The Change in Quality of Life as assessed by Qualiveen Surveys	Evidence of improvement in QoL assessed at Study Days 14 (± 1 day) and 42 and compared to Study Day 0 (baseline) as assessed by the following instrument.	Three time-points across 42 days (Study Day 0 to Study Day 42).
Primary	Safety of TAR-302-5018: Safety will be assessed throughout the study based on reported AEs	Safety will be assessed throughout the study based on reported AEs, investigational product events (IPEs), physical examinations (PEs), vital signs, clinical laboratory tests, scheduled cystoscopic examinations, bladder ultrasounds, bladder post-void residual volume (PVR), and the use of concomitant medications.	Safety will be assessed from the signing of the informed consent form through Study Day 49 (+ 7 days) for a total of up to 77 days.
Secondary	Tolerability of TAR-302-5018	Tolerability will be determined by the proportion of subjects who require TAR-302-5018 removal prior to the planned removal on Day 42 due to meeting any of the Subject Stopping Safety Criteria or other drug or device constituent related adverse event.	Tolerability will be assessed during the 42-day indwelling period unless removed due to lack of tolerability in advance of the Day 42 scheduled removal.
Secondary	Peak Plasma Concentration (Cmax)	Plasma will be evaluated for trospium levels on Study Days 0, 3, 7, 14, 28, 42, and 49.	Seven time-points across 49 days (Day 0 through Day 49).
Secondary	Peak Urine Concentration (Cmax)	Urine will be evaluated for trospium levels on Study Days 0, 3, 7, 14, 28, 42, and 49.	Seven time-points across 49 days (Day 0 through Day 49).
Secondary	Preliminary Urodynamic Efficacy: Vesical Filling Phase - Instillation Volume	Instillation volume at first sensation (mL)	Day 0, Day 14 (+/- 1 day), Day 42
Secondary	Preliminary Urodynamic Efficacy: Vesical Filling Phase - Vesical Pressure	Vesical pressure at first sensation (cmH2O)	Day 0, Day 14 (+/- 1 day), Day 42
Secondary	Preliminary Urodynamic Efficacy: Vesical Filling Phase - Instillation Volume	Instillation volume at first desire to urinate (mL)	Day 0, Day 14 (+/- 1 day), Day 42
Secondary	Preliminary Urodynamic Efficacy: Vesical Filling Phase - Vesical Pressure	Vesical pressure at first desire to urinate (cmH2O)	Day 0, Day 14 (+/- 1 day), Day 42
Secondary	Preliminary Urodynamic Efficacy: Vesical Filling Phase - Instillation Volume	Instillation volume at maximal desire to urinate (mL)	Day 0, Day 14 (+/- 1 day), Day 42
Secondary	Preliminary Urodynamic Efficacy: Vesical Filling Phase - Vesical Pressure	Vesical pressure at maximal desire to urinate (cmH2O)	Day 0, Day 14 (+/- 1 day), Day 42
Secondary	Preliminary Urodynamic Efficacy: Vesical Filling Phase - Instillation Volume	Instillation volume at maximum capacity (mL)	Day 0, Day 14 (+/- 1 day), Day 42
Secondary	Preliminary Urodynamic Efficacy: Vesical Filling Phase - Detrusor Pressure	Detrusor pressure at maximum capacity (cmH2O)	Day 0, Day 14 (+/- 1 day), Day 42
Secondary	Preliminary Urodynamic Efficacy: Vesical Filling Phase - Bladder Compliance	Bladder compliance (mL/cmH2O)	Day 0, Day 14 (+/- 1 day), Day 42
Secondary	Preliminary Urodynamic Efficacy: Involuntary Bladder Contractions - Instillation Volume	Instillation Volume (mL)	Day 0, Day 14 (+/- 1 day), Day 42
Secondary	Preliminary Urodynamic Efficacy: Involuntary Bladder Contractions - Vesical Pressure	Vesical pressure (cmH2O)	Day 0, Day 14 (+/- 1 day), Day 42
Secondary	Preliminary Urodynamic Efficacy: Involuntary Bladder Contractions - Detrusor Pressure	Detrusor pressure (cmH2O)	Day 0, Day 14 (+/- 1 day), Day 42
Secondary	Preliminary Urodynamic Efficacy: Vesical Voiding Phase - Peak Flow	Peak flow (mL/s)	Day 0, Day 14 (+/- 1 day), Day 42
Secondary	Preliminary Urodynamic Efficacy: Vesical Voiding Phase - Mean Flow	Mean flow (mL/s)	Day 0, Day 14 (+/- 1 day), Day 42
Secondary	Preliminary Urodynamic Efficacy: Vesical Voiding Phase - Detrusor Pressure	Detrusor pressure at the peak flow (cmH2O)	Day 0, Day 14 (+/- 1 day), Day 42
Secondary	Preliminary Urodynamic Efficacy: Vesical Voiding Phase - Total Voided Volume	Total voided volume (mL)	Day 0, Day 14 (+/- 1 day), Day 42
Secondary	Preliminary Urodynamic Efficacy: Vesical Voiding Phase - Post Void Residual Volume	Post void residual volume (mL)	Day 0, Day 14 (+/- 1 day), Day 42